key: cord-288919-3ay39zf5
authors: Müller, Helmut; Kniepeiss, Daniela; Stauber, Rudolf; Schrem, Harald; Rauter, Markus; Krause, Robert; Schemmer, Peter
title: Recovery from COVID‐19 following hepatitis C, human immunodeficiency virus infection, and liver transplantation
date: 2020-06-18
journal: Am J Transplant
DOI: 10.1111/ajt.16107
sha: 
doc_id: 288919
cord_uid: 3ay39zf5

Immunosuppression and frequent comorbidities in transplant recipients potentially increase the risk of fatal outcomes of pandemic coronavirus disease 2019 (COVID-19) [1]. A 1965 born male had suffered from haemophilia A. In the nineteen-seventies, he acquired hepatitis C virus (HCV) infection, probably via factor VIII supplementation, and in 1985 human immunodeficiency virus (HIV) infection. Interferon-based HCV therapy resulted in a sustained virological response. Antiviral treatment with emtricitabine/tenofovir alafenamide/rilpivirin for HIV is ongoing since 2016. HIV suppression with repeatedly negative PCR results has been achieved.

To the Editor: 

COVID-19 in longterm liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma

Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement

Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation

Fatal outcome in a liver transplant recipient with COVID-19

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.